Dare Bioscience, Inc. (DARE)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 68/100 (HIGH), 4.5 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 6.27% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Dare Bioscience stock rises after receiving HPV treatment patent
- Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand
- Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth
- Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series
- Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment
- Dare Bioscience Inc (DARE) (Q2 2026) Earnings Call Highlights: Commercial Launch Milestones and ...
- DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List
- Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Letter by Xu et al Regarding Article, "Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial". — Circulation 2026 Sep 15 PMID 42735226
- Response by Zhao et al to Letter Regarding Article, "Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial". — Circulation 2026 Sep 15 PMID 42735225
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Dare Bioscience, Inc..
Full DARE Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.